Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis

Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis

BackgroundUltra-long-acting insulin analogs [insulin degludec (IDeg) and insulin glargine 300 units/mL (IGla-300)] offer a longer duration of action with less risk of hypoglycemia compared to other long-acting insulins. However, data about the comparative efficacy and safety are inconsistent.Methods...

Full description

Bibliographic Details
Main Authors:	Eman N. Alhmoud, Mohamed Omar Saad, Nabil Elhadi Omar
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Endocrinology
Subjects:	insulin diabetes glargine degludec hypoglycemia HbA1c
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1285147/full

Similar Items

United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
by: Rendell M
Published: (2017-04-01)

Effects of Switching from Degludec to Glargine U300 in Patients with Insulin-Dependent Type 1 Diabetes: A Retrospective Study
by: Toshitaka Sawamura, et al.
Published: (2024-03-01)

Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross‐over study
by: Mizuho Yamabe, et al.
Published: (2019-03-01)

Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes
by: Junko Oya, et al.
Published: (2021-11-01)

Effect of switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL (Gla-300) in Brazilian people with type 1 diabetes
by: Patricia Medici Dualib, et al.
Published: (2024-07-01)

Individualisation of basal insulin therapy of type 2 diabetes: evidence from large randomized controlled trials
by: S. V. Nedogoda, et al.
Published: (2023-01-01)

Insulin glargine 300 U/ml in the management of diabetes: clinical utility and patient perspectives
by: de Galan BE
Published: (2016-10-01)

Effect of insulin glargine on glycemic control in adolescents with type 1-diabetes
by: Hassan M. Mona, et al.
Published: (2015-06-01)

Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Yunjiao Yang, et al.
Published: (2022-05-01)

Insulin/carbohydrates ratio during the first 6‐month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. An observational longitudinal study
by: Stefano Tumini, et al.
Published: (2020-04-01)

Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Degludec Due to Hypoglycaemic Variability
by: Valentina Guarnotta, et al.
Published: (2018-07-01)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
by: Lau IT, et al.
Published: (2017-06-01)

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
by: Richard E. Pratley, et al.
Published: (2019-11-01)

ATOS study: effectiveness and safety of insulin glargine 300 U/mL in the real world clinical practice in insulin-naïve type 2 diabetic patients in the Russian Federation
by: Gagik R. Galstyan
Published: (2022-10-01)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
by: Monika Russel-Szymczyk, et al.
Published: (2019-12-01)

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
by: Kyu Yong Cho, et al.
Published: (2020-08-01)

Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
by: Michelle Miller, et al.
Published: (2021-09-01)

Concentrated insulins: the new basal insulins
by: Lamos EM, et al.
Published: (2016-03-01)

The use of long-acting insulin degludec in adult patients with type 2 diabetes mellitus in real clinical practice in Russia
by: G. R. Galstyan
Published: (2023-02-01)

Flexibility in insulin prescription
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
by: Sanjay Kalra, et al.
Published: (2016-01-01)

The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design
by: Rikke Mette Agesen, et al.
Published: (2019-07-01)

rDNA insulin glargine U300 – a critical appraisal
by: Wang F, et al.
Published: (2016-12-01)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
by: Shinje Moon, et al.
Published: (2021-09-01)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01)

Management of diabetic ketoacidosis in children: Does early insulin glargine help improve outcomes?
by: Rebecca Ohman‐Hanson, et al.
Published: (2024-08-01)

On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
by: Yuji Kawaguchi, et al.
Published: (2019-11-01)

Clinical experience in using long-acting human insulin Glargine 300 U/ml in the practice of an endocrinologist
by: O. A. Guseva, et al.
Published: (2018-04-01)

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
by: Minze MG, et al.
Published: (2016-03-01)

Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
by: Elena Valer'evna Biryukova, et al.
Published: (2012-09-01)

Analysis of the quality of life of patients with type 1 diabetes mellitus in real clinical practice who received insulin degludec
by: L. A. Suplotova, et al.
Published: (2021-10-01)

The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes
by: Beljić-Živković Teodora, et al.
Published: (2016-01-01)

Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety
by: E. V. Biryukova, et al.
Published: (2021-09-01)

Comparison of efficacy of detemir and degludec insulin in the management of children and adolescents with type 1 diabetes
by: Bedowra Zabeen, et al.
Published: (2022-01-01)

Characteristics of insulin-Naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials
by: M. H. Cummings, et al.
Published: (2018-05-01)

Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-07-01)

Once-weekly insulin icodec versus once-daily long-acting insulins for type 2 diabetes mellitus: Systematic review and meta-analysis
by: Sandro Augusto Goncalves Ribeiro, et al.
Published: (2024-06-01)

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
by: Thomann R, et al.
Published: (2020-07-01)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
by: Kai‐Jen Tien, et al.
Published: (2019-05-01)